Table 2.
Factors | Variables (n) | % LAR | P |
Preoperative | |||
Age (yr) | < 40 (53) vs ≥ 40 (151) | 12 vs 6 | 0.03 |
Gender | Men (102) vs women (102) | 8 vs 8 | 0.79 |
Disease: Viral | Yes (77) vs No (127) | 9 vs 6 | 0.41 |
Total bilirubin (mg/L) | < 50 (100) vs ≥ 50 (104) | 8 vs 7 | 0.72 |
MELD score | < 10 (123) vs ≥ 10 (81) | 7 vs 9 | 0.57 |
Blood type match | Identical (163) vs compatible (41) | 8 vs 5 | 0.5 |
Gender match | Yes (91) vs No (113) | 9 vs 6 | 0.48 |
Donor age (yr) | < 40 (84) vs ≥ 40 (120) | 10 vs 6 | 0.32 |
HLA-A mismatch (n) | 0 (75) vs 1 or 2 (128) | 9 vs 6 | 0.64 |
HLA-B mismatch (n) | 0 (38) vs 1 or 2 (166) | 11 vs 7 | 0.41 |
HLA-DR mismatch (n) | 0 (43) vs 1 or 2 (161) | 5 vs 8 | 0.44 |
T-LCX | Negative (195) vs positive (9) | 8 vs 0 | 0.39 |
B-LCX | Negative (116) vs positive (88) | 5 vs 7 | 0.71 |
Operative | |||
Anhepatic time (min) | < 150 (116) vs ≥ 150 (88) | 8 vs 7 | 0.8 |
Blood loss (mL/kg) | < 100 (88) vs ≥ 100 (116) | 7 vs 8 | 0.8 |
Graft weight/SLV (%) | < 50 (69) vs ≥ 50 (135) | 7 vs 7 | 0.97 |
Postoperative | |||
Immunosuppressive regimen | FK (166) vs CsA (38) | 32 vs 2 | < 0.0001 |
Proceeding CMV infection | Yes (82) vs No (116) | 7 vs 8 | 0.91 |
Early acute rejection | Yes (61) vs No (143) | 11 vs 6 | 0.14 |
LAR: Late onset acute rejection; MELD: Model for end stage liver disease; HLA-n: Human leukocyte antigen n allele; LCX: Lymphocytotoxic crossmatch; SLV: Standard liver volume; CMV: Cytomegalovirus.